Of more clinical importance, perhaps, are the findings that suggest that miRNAs are potential biomarkers of response to common cancer therapeutics such as chemotherapeutic drugs (5-fluorouracil [62, 63], S-1 [63], paclitaxel [64], cisplatin [64, 65], gemcitabine [66]), hormonal therapy (tamoxifen [67], glucocorticoids [68]), tyrosine kinase inhibitors (sorafenib [69], anti-EGFR TKI [70]), and radiotherapy [71]). Here, EGFR is linked to cancer.